FACTORS THAT INFLUENCE BEMPEDOIC ACID-MEDIATED REDUCTIONS IN HIGH-SENSITIVITY C-REACTIVE PROTEIN: ANALYSIS OF POOLED PATIENT-LEVEL DATA FROM PHASE 3 CLINICAL TRIALS

Reduced high-sensitivity C-reactive protein (hsCRP) levels are associated with lower atherosclerotic cardiovascular disease (ASCVD) risk. Bempedoic acid (BA) is an investigational, ATP-citrate lyase inhibitor in development for treatment of hypercholesterolemia. Prior clinical trial data support BA